Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication helps quell the agitation of dementia

22.07.2004


Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.



The work, led by researchers at the University of Rochester Medical Center, was presented July 22 at the 9th International Conference on Alzheimer’s Disease and Related Disorders in Philadelphia, Pa. The conference is sponsored by the Alzheimer’s Association.

The medication tested in the study, quetiapine, was effective at treating agitation, but with fewer side effects than other medicines that doctors turn to now.


"One of the most stressing and vexing changes in behavior in patients with dementia is agitation, which occurs in about half of patients at some point in their illness," says Pierre Tariot, M.D., professor of Psychiatry, Medicine, and Neurology, who led the study. "This behavior can be terrifying to the family and is one of the major reasons many families end up placing their loved ones in nursing homes."

Agitation is also difficult for doctors to treat. Currently there is no medication approved by the Food & Drug Administration to treat agitation in patients with dementia, though doctors and families often try to quell the symptoms with drugs that have been approved for other uses.

Doctors try anti-psychotic medications that usually reduce incidents such as slapping or yelling at caregivers or family members in about 15 to 20 percent of patients, Tariot says. But such medications can cause side effects like weight gain, high cholesterol, sleepiness, and Parkinson’s-like movement difficulties, and some have recently been linked to higher incidences of cerebrovascular "adverse events" such as strokes and transient ischemic attacks.

"All the drugs used currently, including quetiapine, have drawbacks," says Tariot, who is also a researcher in the university’s Center for Aging and Developmental Biology. "There is no ideal solution. For each patient you have to weigh the benefit of the drug against the potential cost in terms of side effects."

Tariot helped lead the study of quetiapine, a newer type of medication known as an "atypical antipsychotic." In a 10-week study of 333 people in nursing homes, the medication reduced such behaviors about 20 percent more often than a placebo did, comparable to the other drugs now available. In addition, the behavior of patients on the medication was more likely to be rated as "improved" or "very much improved," compared to other patients not on the medicine, by doctors and nurses who did not know which patients were on the medicine and which were not.

Significantly, in Tariot’s study and in another presented at the meeting by Lon Schneider, M.D., of the University of Southern California, the medication has shown no evidence so far of causing serious side effects such as strokes, although it does cause sleepiness in some people.

"Quetiapine appears to show a similar treatment effect as other medications commonly used to treat agitation, but with a side effect profile that may be different from the other agents," says Tariot, who also serves as a paid consultant to AstraZeneca, which makes Seroquel®, the brand name of quetiapine. "If quetiapine remains free of the most worrisome side effects through further studies, that would represent an advantage and would offer a new therapeutic option for patients and their families."

While experienced clinicians often turn to atypical antipsychotics like quetiapine to treat agitation in dementia patients, Tariot says this is the first large, double-blind, placebo-controlled study to evaluate just how well quetiapine works. More information is expected next year, when results are announced from a large study funded by the National Institutes of Health that is the first to compare several atypical antipsychotics – such as quetiapine, risperidone, and olanzapine – for treating Alzheimer’s and schizophrenia.

Before turning to medications, however, Tariot and other experts say the best way to treat dementia patients who are agitated is to try to understand if there is a reason underlying the behavior. Health care workers should make sure the person isn’t in pain, for instance, and that caregiver behavior is appropriate and respectful. Check to see that there aren’t features in the environment that can be easily changed, such as excessive heat or noise, which may be disturbing the patient. Sometimes, distracting a patient or changing the subject, as a parent does with a young child, is helpful. Sometimes other medications used to treat Alzheimer’s disease, such as cholinesterase inhibitors or memantine, can alleviate these behaviors. When all such efforts fail – which they do often in patients with dementia, Tariot says – doctors and families should consider medication.

"It’s clear that Alzheimer’s will be the pandemic of the West in the next century," Tariot says. "Right now there are approximately 4.5 million Americans with dementia, and that number is expected to triple over the next few decades. Many of these patients will experience significant change in their emotions and personality. It’s imperative that we find better treatments as soon as possible."

Tom Rickey | EurekAlert!
Further information:
http://www.urmc.rochester.edu

More articles from Health and Medicine:

nachricht A 'half-hearted' solution to one-sided heart failure
24.11.2017 | Boston Children's Hospital

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>